| Original language | English (US) |
|---|---|
| Pages (from-to) | 734-735 |
| Number of pages | 2 |
| Journal | Annals of neurology |
| Volume | 91 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2022 |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS. / Zeydan, Burcu; Rocca, Maria A.; Kantarci, Orhun H. et al.
In: Annals of neurology, Vol. 91, No. 5, 05.2022, p. 734-735.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS
AU - Zeydan, Burcu
AU - Rocca, Maria A.
AU - Kantarci, Orhun H.
AU - Filippi, Massimo
N1 - Funding Information: Dr. Zeydan reported receiving funding from National Institutes of Health (U54 AG 44170), Dr. Rocca reported receiving speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva, and receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Kantarci reported no disclosures. Dr. Filippi reported is Editor‐in‐Chief of the , Associate Editor of , Associate Editor of , and Associate Editor of ; received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck‐Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck‐Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Journal of Neurology Human Brain Mapping Radiology Neurological Sciences Funding Information: Dr. Zeydan reported receiving funding from National Institutes of Health (U54 AG 44170), Dr. Rocca reported receiving speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva, and receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Kantarci reported no disclosures. Dr. Filippi reported is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences; received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85126487198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126487198&partnerID=8YFLogxK
U2 - 10.1002/ana.26341
DO - 10.1002/ana.26341
M3 - Letter
C2 - 35253269
AN - SCOPUS:85126487198
SN - 0364-5134
VL - 91
SP - 734
EP - 735
JO - Annals of Neurology
JF - Annals of Neurology
IS - 5
ER -